Home
>
National Drug Code (NDC)
>
Aspirin, Caffeine, and Dihydrocodeine Bitartrate
Aspirin, Caffeine, and Dihydrocodeine Bitartrate - 57664-419-88 - (Aspirin, Caffeine, and Dihydrocodeine Bitartrate)
Drug Information of Aspirin, Caffeine, and Dihydrocodeine Bitartrate
| Product NDC: | 57664-419 |
| Proprietary Name: | Aspirin, Caffeine, and Dihydrocodeine Bitartrate |
| Non Proprietary Name: | Aspirin, Caffeine, and Dihydrocodeine Bitartrate |
| Active Ingredient(s): | 356.4; 30; 16 mg/1; mg/1; mg/1 & nbsp; Aspirin, Caffeine, and Dihydrocodeine Bitartrate |
| Administration Route(s): | ORAL |
| Dosage Form(s): | CAPSULE |
| Coding System: | National Drug Codes(NDC) |
Labeler Information of Aspirin, Caffeine, and Dihydrocodeine Bitartrate
| Product NDC: | 57664-419 |
| Labeler Name: | Caraco Pharmaceutical Laboratories, Ltd |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | NDA011483 |
| Marketing Category: | NDA AUTHORIZED GENERIC |
| Start Marketing Date: | 20121001 |
Package Information of Aspirin, Caffeine, and Dihydrocodeine Bitartrate
| Package NDC: | 57664-419-88 |
| Package Description: | 100 CAPSULE in 1 BOTTLE (57664-419-88) |
NDC Information of Aspirin, Caffeine, and Dihydrocodeine Bitartrate
| NDC Code | 57664-419-88 |
| Proprietary Name | Aspirin, Caffeine, and Dihydrocodeine Bitartrate |
| Package Description | 100 CAPSULE in 1 BOTTLE (57664-419-88) |
| Product NDC | 57664-419 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | Aspirin, Caffeine, and Dihydrocodeine Bitartrate |
| Dosage Form Name | CAPSULE |
| Route Name | ORAL |
| Start Marketing Date | 20121001 |
| Marketing Category Name | NDA AUTHORIZED GENERIC |
| Labeler Name | Caraco Pharmaceutical Laboratories, Ltd |
| Substance Name | ASPIRIN; CAFFEINE; DIHYDROCODEINE BITARTRATE |
| Strength Number | 356.4; 30; 16 |
| Strength Unit | mg/1; mg/1; mg/1 |
| Pharmaceutical Classes | Cyclooxygenase Inhibitors [MoA],Decreased Prostaglandin Production [PE],Nonsteroidal Anti-inflammatory Compounds [Chemical/Ingredient],Nonsteroidal Anti-inflammatory Drug [EPC],Central Nervous System Stimulant [EPC],Central Nervous System Stimulation [PE],Methylxanthine [EPC],Xanthines [Chemical/Ingredient],Full Opioid Agonists [MoA],Opioid Agonist [EPC] |
